Thermo Fisher Scientific Inc.
TMO · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $198,727,860 | $204,884,940 | $215,870,480 | $262,892,560 |
| - Cash | $4,009,000 | $8,083,000 | $8,524,000 | $4,477,000 |
| + Debt | $32,775,000 | $36,424,000 | $36,073,000 | $36,339,000 |
| Enterprise Value | $227,493,860 | $233,225,940 | $243,419,480 | $294,754,560 |
| Revenue | $42,879,000 | $42,857,000 | $44,915,000 | $39,211,000 |
| % Growth | 0.1% | -4.6% | 14.5% | – |
| Gross Profit | $17,728,000 | $17,194,000 | $19,011,000 | $19,634,000 |
| % Margin | 41.3% | 40.1% | 42.3% | 50.1% |
| EBITDA | $11,800,000 | $11,195,000 | $11,942,000 | $11,969,000 |
| % Margin | 27.5% | 26.1% | 26.6% | 30.5% |
| Net Income | $6,335,000 | $5,995,000 | $6,950,000 | $7,725,000 |
| % Margin | 14.8% | 14% | 15.5% | 19.7% |
| EPS Diluted | 16.53 | 15.45 | 17.64 | 19.46 |
| % Growth | 7% | -12.4% | -9.4% | – |
| Operating Cash Flow | $8,667,000 | $8,406,000 | $9,154,000 | $9,543,000 |
| Capital Expenditures | -$1,400,000 | -$1,479,000 | -$2,243,000 | -$2,523,000 |
| Free Cash Flow | $7,267,000 | $6,927,000 | $6,911,000 | $7,020,000 |